Skip to main content

Table 3 Results of Cox proportional hazard regression analyses in mrEF

From: Differing effects of beta-blockers on long-term clinical outcomes following percutaneous coronary intervention between patients with mid-range and reduced left ventricular ejection fraction

 

Univariable

Multivariable

HR

95% CI

p

HR

95% CI

p

Age: 1-year increase

1.04

1.02–1.06

 < 0.001

1.03

1.01–1.05

0.007

Men: yes

0.70

0.44–1.17

0.164

   

Hypertension: yes

1.18

0.78–1.83

0.438

   

Diabetes Mellitus: yes

1.44

0.97–2.16

0.073

1.56

1.04–2.35

0.033

CKD (eGFR < 60 mL/min/1.73m2): yes

1.60

1.05–2.41

0.028

1.24

0.80–1.91

0.345

Family History of IHD: yes

0.73

0.44–1.18

0.204

   

Current smoking: yes

0.60

0.35–0.97

0.037

0.81

0.47–1.40

0.435

LDL-C: 1 mg/dL increase

1.00

0.99–1.00

0.164

   

HDL-C: 1 mg/dL increase

0.99

0.98–1.01

0.258

   

LVEF: 1% increase

0.97

0.91–1.04

0.368

   

Multivessel disease: yes

1.27

0.84–1.96

0.256

   

Acute Coronary Syndrome: yes

1.19

0.79–1.77

0.407

   

Statins use: yes

0.60

0.40–0.90

0.013

0.65

0.43–0.98

0.040

ACEIs/ARBs use: yes

1.12

0.73–1.78

0.609

   

Aspirin use: yes

0.81

0.42–1.82

0.586

   

Beta blocker use: yes

0.74

0.49–1.10

0.137

   
  1. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CI confidence interval, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, HDL-C high-density lipoprotein cholesterol, HR hazard ratio, IHD ischemic heart disease, LDL-C low-density lipoprotein cholesterol, LVEF left ventricular ejection fraction, mrEF mid-range ejection fraction
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us